Consolati, A.; Farinelli, M.; Serravalle, P.; Rollandin, C.; Apprato, L.; Esposito, S.; Bongiorno, S.
Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season. Vaccines 2024, 12, 549.
https://doi.org/10.3390/vaccines12050549
AMA Style
Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, Bongiorno S.
Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season. Vaccines. 2024; 12(5):549.
https://doi.org/10.3390/vaccines12050549
Chicago/Turabian Style
Consolati, Alessandra, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, and Salvatore Bongiorno.
2024. "Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season" Vaccines 12, no. 5: 549.
https://doi.org/10.3390/vaccines12050549
APA Style
Consolati, A., Farinelli, M., Serravalle, P., Rollandin, C., Apprato, L., Esposito, S., & Bongiorno, S.
(2024). Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season. Vaccines, 12(5), 549.
https://doi.org/10.3390/vaccines12050549
